- William E. Lyddane
- Jonathan R. Miller*
- Daniel B. Moon
- Robert W. Mueller
- Sean C. Myers-Payne, Ph.D.
- Naoko Ohashi*
- Leslie J. Paperner*
- Enoch E. Peavey
- P. Branko Pejic*
- William Pieprz*
- Steven Pollicoff*
- John Preta*
- James L. Rowland
- Stephen M. Roylance
- Kenneth H. Salen
- Walter Schlapkohl, Ph.D.
- Timothy S. Schwarz
- Bruce H. Stoner, Jr.
- Arnold Turk
- Christopher L. Wright, Ph.D.*
- Patent Agents
- Patent Specialists
- Technical Advisor
Stephen M. Roylance
Firm Practice Areas/Practice Groups
Client Counseling, Licensing and Technology Transfer
Litigation and Trial
Owner/Manager, Patent Search Firm – 1978-1984
Patent Agent, Private Practice – 1984-1988
Patent Attorney, Private Practice – 1988-1992
Patent Attorney – Greenblum & Bernstein, P.L.C. – 1992-Present
Membership Committee GPHA – 2003-Present
Coordinates and supervises patent prosecution in Biotechnology, Chemical, and Pharmaceutical areas.
Coordinates strategy and activities in Client Counseling, Licensing and Technology Transfer, and Litigation and Trial areas.
Lectures frequently on U.S. Patent Law in Japan.
Professional Associations and MembershipsAmerican Association of Pharmaceutical Scientists
American Bar Association
American Chemical Society
American Intellectual Property Law Association
Generic Pharmaceutical Association
Licensing Executives Society
Roylance, Stephen M., (2016). “FDA Issues Draft Guidance on Updating Labels for Generic Drugs”. Journal of Generic Medicines, First Published September 28, 2016, (DOI: 10.1177/1741134316670698).
Roylance, S. (2013) “The Role of the Citizen's Petition Amendment to the FDCA in Preventing Delays to Generic Approvals.” Journal of Generic Medicines, Pre-published online July 8, 2013 under Digital Object Identifier: 10.1177/1741134313494205
Roylance. S., (2010). “Waiver of the Attorney – Client Privilege Pitfalls for the Unwary.” 7 Journal of Generic Medicines 287-93.
Greenblum, N., Fink, M., Roylance. S., Pejic, P.B., Myers-Payne, S.C., Braier, P., (2008). “Generic Drugs in a Changing Intellectual Property Landscape.” The Pharmaceutical Regulatory Process, Second Edition, pps. 143-180, Ira R. Berry and Robert P. Martin, eds., Informa Health Care
Braier, P., Roylance. S., Greenblum. B., (2005). “U.S. Case Law Developments in 2005.” 3 Journal of Generic Medicines 237-43.
Roylance. S., (2004). “Authorized Generics: Unlikely Alliances Yield Yet Another Controversy.” 2 Journal of Generic Medicines 71-75.
EducationUniversity of Maryland, B.A. (1978)
George Mason University School of Law, J.D. (1988)
1991, U.S. Court of Appeals for the Federal Circuit
1992, U.S. District Court for the District of Maryland